After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S.

TD Cowen raised the firm’s price target on Alnylam (ALNY) to $371 from $282 and keeps a Buy rating on the shares. The firm updated its ...

Scotiabank started coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

AbbVie ABBV announced that the FDA has approved its subcutaneous administered drug ABBV-951 to treat motor fluctuations in ...

Amicus Therapeutics FOLD announced that it has signed a licensing agreement with Teva Pharmaceuticals TEVA, which resolves the patent lawsuit filed earlier by FOLD. The litigation arose after Teva ...

Alnylam Pharma (ALNY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick ...

Alnylam's Yvonne Greenstreet, at #STATSummit, predicts vutrisiran will become multibillion-dollar product for ...

ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR ...

Here is how Alnylam Pharmaceuticals (ALNY) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Fintel reports that on October 16, 2024, Scotiabank initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

While Judo Bio was preparing for its public launch, so was another siRNA start-up. City Therapeutics, the latest project of ...